Pushor Mitchell LLP is pleased to have acted as legal counsel to GeneTether Therapeutics Inc. in connection with its initial public offering of Units. In connection with its IPO, GeneTether issued a total of 7,500,000 Units at a price of $0.60 per Unit for aggregate gross proceeds $4,500,000. GeneTether Therapeutics Inc.’s common shares are listed for trading on the Canadian Securities Exchange under the symbol “GTTX”.
Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Company’s wholly-owned platform technology uses a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTether’s proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTether’s technology.
The Pushor Mitchell team was led by Keith Inman and included assistance from Rebecca Dickson.
